CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the journal, Plastic and Reconstructive Surgery—Global Open, featuring the results of study which compared the use of Renuvion’s Helium Plasma Technology to InMode’s Bipolar RF System (“Bipolar RF”) following liposuction or body contouring procedures.
In this retrospective, single-center, contiguous series study, researchers Michael Kluska, DO et al. collected demographic, procedure and safety data from more than 450 patients who underwent treatment with either Renuvion (n=229) or Bipolar RF (n=236) following liposuction or body contouring procedures. The demographic characteristics of both groups exhibited similarity in terms of age, sex, BMI and tobacco usage.
The researchers analyzed adverse events documented during and post-procedure by body area for both groups. Based on this analysis, they found that the group treated with Renuvion exhibited statistically significant fewer adverse events (p-value <0.0001), compared to the group treated with Bipolar RF. Specifically, 45 adverse events were documented in 34 of the patients treated with Renuvion, compared to 93 adverse events documented in 62 of the patients treated with Bipolar RF. 28 adverse events documented in the Renuvion group were determined to be procedure-related, compared to 69 events in the Bipolar RF group. The researchers found the significantly fewer occurrences of burns, hematoma, hypertrophic scar, and seroma in the Renuvion group to be particularly noteworthy.
Based on these findings, the researchers concluded that Renuvion may offer a safer alternative to Bipolar RF following liposuction or body contouring procedures. They observed that the study’s findings underscore the importance of carefully selecting the appropriate energy-based technology for managing skin laxity following liposuction or body contouring procedures, and added that Renuvion emerges as a promising option over Bipolar RF due to its superior safety profile, shorter procedural times and higher patient satisfaction rates compared to Bipolar RF.
“We are pleased to see the results of this important clinical study published in a peer-reviewed, open access journal, following its presentation at the American Academy of Cosmetic Surgery Scientific Meeting earlier this year,” said Charlie Goodwin, President and Chief Executive Officer. “Its findings support the enhanced safety outcomes that can be achieved when using Renuvion to treat loose skin following liposuction or body contouring procedures, as compared to a commonly-used competing technology. Apyx Medical remains committed to bringing innovative, evidence-based medicine to surgeons and patients in the global cosmetic surgery market, and we believe the study represents an important addition to the extensive body of clinical evidence supporting the safety and efficacy of our Renuvion technology.”
A digital version of the clinical publication is available via the following link: Plastic and Reconstructive Surgery – Global Open (lww.com)
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website www.ApyxMedical.com.